Key Takeaways
- Volume-led 9% FY25 growth, margin jumps to 31%: Revenue reached ₹3,723 crores, driven by general medicines volume up 8%, specialty up 35%, and pediatric vaccines up 12%; EBITDA margin expanded 500 bps to 31% on gross margin improvement and operating leverage.
- Q4 softened on antibiotics, but new platforms are scaling: Q4 revenue growth of 6% was muted by a soft anti-infectives quarter, while Shingrix hit ~20,000 quarterly doses and two global oncology assets received marketing authorization for launch next month.
- Oncology is the next growth leg, starting now: Jemperli (endometrial cancer) and Zejula (ovarian cancer) will launch in the coming months, backed by a new business head, medical investments, and 19 ongoing global clinical trials in India to reduce future launch lags.
- Margins have peaked for now, with investment spend ahead: Management expects to sustain the 31.4% annual margin, not expand it further, as low-hanging fruit is captured and investment in oncology and new platforms must ramp up.
- What to watch next quarter: The pace of the first two oncology launches, Shingrix's monthly dose trajectory beyond the 10,000 mark, and whether the volume-led strategy can sustain above-market growth in FY26 without price levers.
Volume-Led Growth Engine
- General medicines brands hold leadership: Augmentin maintained market leadership in anti-infectives, Ceftum and T-Bact improved market shares, and the evolution index stayed ahead of 100 despite a ~3% external growth suppression in anti-infectives.
- Volume strategy is deliberate, not forced: With 11–12 large brands each doing ₹100–150 crores-plus annually, every incremental prescription multiplies significantly, making volume-led growth preferable to price-led growth.
- Pricing levers are limited by design: More than half the general medicines portfolio is under NLEM price control, so no price hikes were taken last year; for the remaining ~60%, increases are taken but get blended down by an increased NLEM discount strategy and vaccine competitiveness.
- IQVIA data understates performance: IQVIA reporting does not align with GSK's innovative effects and vaccines for both growth and base, causing a disconnect where IQVIA shows 1–2% growth or decline while actual performance is stronger.
- Doctor reach expanded 40% via digital: Face-to-face coverage was optimized downward, but omni-channel digital strategy dialed up total reach to over 400,000 unique HCP touchpoints, with 2,75,000 unique HCPs covered and additional consented digital reach via emailers and WhatsApp.
Bhushan Akshikar: "Clearly, what defines the success of some of these iconic assets that we have in the general medicines portfolio is the science behind why some of these brands continue to be, as I keep saying, not trademarks, but these are trust marks."
Oncology: The Next Growth Platform
- First two assets launch next month: Marketing authorization received for Dostarlimab (Jemperli) for endometrial cancer and Niraparib (Zejula) for ovarian cancer; Zejula launches as first-line maintenance treatment in ovarian cancer, Jemperli as second-line for endometrial cancer with first-line pursuit to follow global strategy.
- Infrastructure build-out is underway: A new oncology business head is in place, recruitments are in full swing, and significant investments have been made on the medical side.
- 19 global clinical trials running in India: Trials span oncology and hepatology, including a potential first functional cure for chronic hepatitis B; the explicit goal is to reduce the drug lag and launch lag for future assets.
- Target oncologist universe is small and specialist: There are only ~1,500 medical oncologists in India, so small, focused teams are being built rather than a broad sales force.
- No TAM or revenue projections disclosed: Management described indications and prevalence but declined to provide specific market size, competitive landscape details, or revenue projections for the two oncology assets, asking investors to wait for data readouts.
Shingrix & Adult Vaccination Ecosystem
- Q4 inflection to 10,000 monthly doses: After several quarters of awareness-building, Shingrix delivered ~20,000 doses in Q4, with 10,000 doses in March alone, moving up from a 2,000–4,000 monthly run-rate earlier.
- Strategy pivoted to clinic partnerships: The go-to-market approach shifted to partnering with 4,000 clinics and major hospitals, with the sales force positioned as "adult vaccination ecosystem creators" rather than traditional sales reps.
- Addressable population is large, adoption is non-linear: Over 1.2 crore Indians aged 50-plus are eligible; management describes the build as an "endurance sport" where every quarter brings learning, not a sprint.
- RSV vaccine is the next adult vaccine in the pipeline: Trials are ongoing in India for the RSV (respiratory syncytial virus) vaccine, which would follow Shingrix in the adult vaccination portfolio.
Bhushan Akshikar: "I always say it's not a 100-meter sprint. It's an endurance sport where every quarter, every year you're learning, you're creating something different."
Respiratory & Specialty Portfolio
- Trelegy Ellipta is the cornerstone of future respiratory strategy: The single-inhalation triple therapy created new benchmarks in Q4 in evolution index and patient reach; it is the biggest global asset in the general medicines portfolio and the largest growth driver in the respiratory space.
- Nucala also set new benchmarks: Alongside Trelegy, Nucala delivered new highs in evolution index and patient reach in Q4.
Margins, Cash & Investment Capacity
- 500 bps margin expansion driven by gross margin and leverage: EBITDA margin improved from 26% to 31% predominantly on better pricing on both sides, raw material costs, and operating leverage; SG&A as a percentage of sales decreased close to 4 percentage points, and field productivity improved 9 percentage points.
- Employment cost leverage was a major contributor: Employment cost fell to 15.7% as a percentage of sales, down significantly, driving operating leverage.
- Margins to sustain, not expand further: Management expects to sustain the annual margin of 31.4% with no big upward change, as the low-hanging fruit has already been captured and the company is at a stabilization stage.
- Investment capacity is intact: All profits converted to cash, the company is zero-debt with ~₹2,500 crores cash, and the endeavor is to hold margins while investing in new business lines like oncology.
- Manufacturing is largely local: 99% of general medicines are locally manufactured, one-third from the company's own Nashik site and two-thirds from 20 CMOs; only inhalers come from outside India.
Bhushan Akshikar: "Our endeavour will be to sustain that margin, annual margin as opposed to seeing any opportunities for further expansion. Having said that, I think, which also means our ability to invest in the new business line, especially in the high growth areas like oncology."
Pipeline & Long-Term Bets
- Beyond the first two oncology assets, a broader pipeline is coming: A slew of products in oncology and vaccines sit beyond Jemperli and Zejula, with Jemperli alone having ongoing trials in several other indications that will each open new opportunities.
- Line extensions sustain big brands: Continued focus on launching line extensions for big brands like Calpol, Augmentin, and Eltroxin to extend their life cycles.
- Generic prescribing debate is a monitored risk: Supreme Court hearings are ongoing on generic prescribing regulations; management's stance is that brand trust matters because "even one patient's life cannot be taken at risk with," and the industry is engaged, but no specific contingency plans were detailed.
- Export opportunity is not on the table: Past sourcing and current WHO manufacturing capability exist, but exports to Southeast Asia and Africa are "not a part of the remit right now," with focus squarely on the innovation pipeline.
Bhushan Akshikar: "I'm not going to focus only on the next five years. I think the organization has outlived generations based on the trust. So, that's where our focus will be."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Oncology launches | Jemperli (endometrial cancer) and Zejula (ovarian cancer) go off the block | Next month |
| FY26 growth | Grow above the IQVIA-prognosed market growth of 8–9% | FY2026 |
| Margin sustainability | Sustain annual EBITDA margin at ~31.4%, no further expansion expected | Ongoing |
| Investment while holding margins | Endeavor to hold margins while investing in oncology and new platforms | Ongoing |
| Shingrix progress updates | Continue sharing progress every quarter | Quarterly |
| Volume-led strategy | Volume-led growth will continue | Ongoing |
| Jemperli first-line pursuit | Pursue first-line indication for endometrial cancer in line with global strategy | Undated, trials ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹3,723 cr, +9% YoY (full year), predominantly volume-led |
| Q4 revenue growth | 6%, predominantly volume-led |
| General medicines volume growth | 8% (full year) |
| Specialty segment growth | 35% (full year) |
| Pediatric vaccines growth | 10% (Q4), 12% (full year) |
| EBITDA | ₹1,169 cr, +30% YoY (full year) |
| EBITDA margin | 31.4% (full year), up from 26% last year; Q4 exit margin ~34% per analyst reference |
| PAT growth | 36% (Q4), 32% (full year) |
| EPS growth | 32% (full year) |
| Cash on balance sheet | ~₹2,500 cr, zero debt |
| Final dividend | ₹42 per share, in addition to interim dividend |
| Employment cost as % of sales | 15.7% |
| SG&A as % of sales | Decreased ~4 percentage points (full year) |
| Field productivity | Improved 9 percentage points (full year) |
| Portfolio under NLEM price control | 38% |
| Shingrix doses | ~20,000 doses in Q4, touching 10,000 doses in March alone |
| New growth platforms revenue (Trelegy, Nucala, Shingrix) | ~₹120–₹130 cr annual revenues |
| Unique HCP touchpoints (omni-channel) | Over 400,000 |
| Distinct HCPs covered face-to-face | 2,75,000 |
| Reach increase via digital | Up by more than 40% on top of previous coverage |
| Anti-infectives market external growth | ~3% |
| Brands with annual revenue >₹100–₹150 cr | 11–12 brands |
| Brands in top 20–30 pharma industry rankings | At least 3–4, including the number one brand |
| General medicines local manufacturing | 99% locally manufactured; one-third from own Nashik site, two-thirds from 20 CMOs |
| Adult vaccination ecosystem target clinics | ~4,000 clinics |
| Indians aged 50+ eligible for shingles prevention | More than 10 to 1.2 crore |
| Ovarian cancer prevalence | ~6.6 per lakh population |
| Oncology launches planned | Jemperli (endometrial cancer) and Zejula (ovarian cancer), launching in coming months |